<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Increased coagulation has been associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> and progression </plain></SENT>
<SENT sid="1" pm="."><plain>Mainly small studies have addressed the association between clotting factor gene polymorphisms and the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the association between six well-known clotting factor gene polymorphisms and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk in a large case-control study </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: Factor V Leiden (rs6025), prothrombin G20210A (rs1799963), PAI-1 4G/5G (rs1799889), MTHFR 677C&gt;T (rs1801133), fibrinogen gamma 10034C&gt;T (rs2066865), and factor XIII Val34Leu (rs5985) were genotyped in 1,801 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and 1,853 healthy controls from a large German population-based study </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> associated with gene variants was determined by calculating odds ratios (ORs) and their 95% CIs using logistic regression </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Homozygous carriers of the prothrombotic factor V Leiden polymorphism showed a 5.8-fold increased risk (95% CI, 1.69 to 19.72) for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> compared with noncarriers </plain></SENT>
<SENT sid="6" pm="."><plain>A 30% reduced risk was found for heterozygous carriers of factor V Leiden (OR = 0.68; 95% CI, 0.52 to 0.90) and prothrombin G20210A (OR = 0.69; 95% CI, 0.49 to 0.96), implying an advantage for slightly increased thrombin generation </plain></SENT>
<SENT sid="7" pm="."><plain>Carriers of the antithrombotic factor XIII Val34Leu polymorphism showed a 15% reduced risk of developing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (OR = 0.85; 95% CI, 0.74 to 0.97) compared with noncarriers </plain></SENT>
<SENT sid="8" pm="."><plain>Our results did not support an effect of PAI-1 4G/5G, MTHFR 677C&gt;T, and fibrinogen gamma 10034C&gt;T on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Our results support a role of clotting factor polymorphisms and thereby the coagulation system in the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>